Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
Mallinckrodt plc (MNK) delivers specialty pharmaceutical solutions and medical imaging innovations across autoimmune, rare disease, and diagnostic markets. This news hub provides investors and healthcare professionals with essential updates on the company’s strategic developments and regulatory milestones.
Access timely reports on earnings announcements, product approvals, research advancements, and partnership agreements. Our curated collection features official press releases alongside verified third-party coverage of MNK’s activities in specialty generics, contrast media production, and therapeutic pipeline progress.
Key content categories include financial performance updates, manufacturing capacity expansions, intellectual property developments, and compliance-related communications. Track MNK’s progress in neurology, rheumatology, and nephrology treatment innovations through objective reporting of material events.
Bookmark this page for streamlined monitoring of Mallinckrodt’s operational updates and market positioning. Check back regularly for authoritative coverage of this specialty pharma leader’s initiatives in addressing complex healthcare challenges through advanced biopharmaceutical solutions.
Mallinckrodt (NYSE:MNK) announced support for the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation and observed annually on October 14 during National Liver Awareness Month.
The initiative aims to raise awareness, promote early detection and treatment, and share patient experiences. HRS is described in two types: HRS‑AKI (rapid, often requiring hospitalization) and HRS‑CKD (slower progression). The release states HRS affects more than 60,000 Americans annually (~0.01% of the U.S. population) and that hospitalization rates for HRS are increasing. Company and ALF leaders commented on the need to improve visibility and treatment options for patients.
Mallinckrodt (NYSE:MNK) has published findings from a cross-sectional physician survey and medical chart review regarding Acthar® Gel treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The study, published in Open Access Rheumatology: Research and Reviews, demonstrated that some patients experienced positive treatment outcomes including reduced symptoms, decreased pain, improved physical function, and reduced corticosteroid use.
Acthar Gel, an FDA-approved complex mixture of ACTH analogs and pituitary peptides, is indicated for treating various autoimmune disorders and inflammatory conditions. The research provides valuable real-world data on the medication's clinical application and effectiveness in treating these complex arthritic conditions.
Mallinckrodt (MNK) has appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently EVP and CFO at Incyte, will succeed Bryan Reasons, who is departing to pursue other opportunities.
With approximately 30 years of biotechnology industry experience, Stamoulis brings extensive expertise in strategy, finance, and corporate development. Her appointment follows Mallinckrodt's recent merger with Endo, marking a significant transformation period for the company. In her new role, she will oversee the finance organization and lead corporate development initiatives.
Prior to Incyte, Stamoulis held leadership positions at Unum Therapeutics, Vertex Pharmaceuticals, and served as Managing Director at Citigroup's Investment Banking division. She holds two BS degrees and an MBA from MIT.
Mallinckrodt (MNK) reported Q2 2025 financial results and provided guidance following its merger with Endo. Legacy Mallinckrodt achieved net sales of $485.1M (down 5.7% YoY, but up 8.5% excluding Therakos divestiture) and net income of $2.4M. Legacy Endo reported flat revenues of $447.8M with a net loss of $59.6M.
Key highlights include Acthar Gel's highest growth in over a decade (up 48.8% to $175.1M) and XIAFLEX's 9.4% growth to $138.6M. The combined company projects 2025 net sales of $3.57B-$3.62B and adjusted EBITDA of $1.10B-$1.13B. The planned spin-off of Par Health remains on track for Q4 2025, with expected net sales of $1.72B-$1.75B.
The company raised Acthar Gel's 2025 growth guidance to 20-30% from high-single digits and reaffirmed XIAFLEX's high-single digit growth outlook.Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.
The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.
Mallinckrodt (NYSE:MNK) and Endo have completed their merger to create a global therapeutics leader. Under the deal terms, Endo shareholders received $100 million in cash and will own 49.9% of Mallinckrodt, while pre-transaction Mallinckrodt shareholders retain 50.1% ownership.
The merger includes plans to spin off their combined generics and sterile injectables business (Par Health) as an independent company by Q4 2025. The company expects to achieve $150 million in annual pre-tax synergies by Year 3, with $75 million in the first year. A $1.35 billion secured credit facility was established to refinance debt and fund the transaction.
Post spin-off, the branded therapeutics company will seek NYSE listing. Siggi Olafsson continues as CEO, with Paul Efron serving as Board Chair of the combined entity.
Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.
Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.
